PULSE BIOSCIENCES, INC.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(66,289) | $(55,348) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 270 | 313 |
| Amortization of intangible assets | 500 | 499 |
| Stock-based compensation | 12,197 | 16,487 |
| Accretion of discounts on marketable securities | (204) | — |
| Non-cash lease expense | 951 | 847 |
| Write-off of deferred issuance costs | 281 | — |
| Other | 20 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (23) | (15) |
| Inventory | (96) | (57) |
| Prepaid expenses and other current assets | (216) | (552) |
| Other non-current assets | 12 | (28) |
| Accounts payable | 166 | 1,318 |
| Accrued liabilities | 5,021 | (1,823) |
| Lease liabilities, net | (1,167) | (1,008) |
| Net cash used in operating activities | (48,577) | (39,367) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (152,348) | — |
| Purchases of property and equipment | (265) | (210) |
| Purchases of intangible assets | — | (20) |
| Net cash used in investing activities | (152,613) | (230) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under at-the-market offering program, net of issuance costs | 142,743 | — |
| Proceeds from exercises of stock options | 11,662 | 2,100 |
| Proceeds from issuance of common stock under employee stock purchase plan | 800 | 593 |
| Proceeds from exercises of warrants, net of issuance costs | 1,975 | 14,080 |
| Net cash provided by financing activities | 157,180 | 16,773 |
| Net decrease in cash and cash equivalents | (44,010) | (22,824) |
| Cash and cash equivalents at beginning of period | 80,735 | 118,038 |
| Cash and cash equivalents at end of period | $36,725 | $95,214 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Proceeds from exercise of stock options not yet received | $38 | $— |
| Unpaid at-the-market offering program issuance costs | $83 | $— |
| Unpaid amounts related to purchase of equipment | $35 | $24 |
| Unpaid warrant issuance costs | $— | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.